By IDSE News Staff
The FDA approved a single-dose, live-attenuated chikungunya virus (CHIKV) vaccine (Ixchiq, Valneva) to prevent the disease in those 18 years of age and older who are at increased risk for exposure to CHIKV.
The indication was approved under an accelerated approval based on anti-CHIKV neutralizing antibody titers. The final pivotal phase 3, double-blind, multicenter study was done in 43 vaccine trial sites in the United States among 4,128 participants who were 18 years old